Form 4: Brainstorm Cell Therapeutics Director Acquires Shares Through Stock Incentive Plan

Director Anthony J. Polverino acquired 24,000 shares of Brainstorm Cell Therapeutics through a restricted stock unit award.

Summary

• On January 1, 2025, Anthony J. Polverino, a director of Brainstorm Cell Therapeutics Inc., acquired 24,000 shares of common stock through a restricted stock unit (RSU) award under the 2014 Stock Incentive Plan.
• The RSUs vest in two tranches: 50% on the grant date and the remaining 50% six months later, contingent upon continued employment.
• The acquisition price was $0.00 per share.
• Following the transaction, Polverino directly owns 25,730 shares.
• The filing also notes a 1-for-15 reverse stock split that took place on October 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of shares through a stock incentive plan. While insider buying can be seen as positive, it's part of a pre-determined compensation plan.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company director.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Anthony J. Polverino, Director, Stock Incentive Plan, Restricted Stock Units, RSU, Beneficial Ownership, Form 4, Reverse Stock Split